Privia Health Group, Inc. Common Stock
PRVAPrivia Health Group, Inc. is a healthcare technology and services company that connects physicians, patients, and payers through a platform designed to improve care coordination and outcomes. Founded in 2013, it offers practice management, technology solutions, and value-based care programs to enable independent physicians to deliver high-quality, affordable care.
Company News
Hedge fund Rubicon Founders increased its stake in Privia Health Group by 175,142 shares in Q1 2026, with the stock now representing 88.92% of the fund's portfolio. The move signals bullish sentiment, supported by Privia's strong financial performance including 26% YoY revenue growth in Q1 2026 and 59% net income growth in 2025, positioning it as...
Cross Keys Capital served as exclusive financial advisor to the Neurology Group of Bergen County (NGBC) in its partnership with Privia Health. NGBC, a 50-year-old independent neurology practice in New Jersey with 25 clinicians, partnered with Privia to expand access to neurological care while maintaining its independent culture. The transaction t...
Privia Health Group announced a definitive agreement to expand into New Jersey through a partnership with Neurology Group of Bergen County (NGBC), a 25-clinician neurology practice. NGBC will serve as the anchor practice for Privia Medical Group—New Jersey and is expected to be implemented on the Privia Platform by year-end 2026. The partnershi...
Privia Health Group announced Q1 2026 financial results showing strong performance with total revenue of $603.8M (up 25.8% YoY), practice collections of $914.8M (up 14.6%), and adjusted EBITDA of $36.7M (up 36.3%). The company maintained most of its full-year 2026 guidance while raising attributed lives guidance to 1.6-1.625 billion. Key operatio...
Privia Health Group's CFO David Mountcastle sold 13,018 shares worth approximately $283,000 over March 12-13, 2026, to cover tax obligations from vesting stock units. The sale represented 5.24% of his direct holdings. Despite a 10% stock price decline in 2026, the company reported strong Q4 FY2025 earnings, exceeding expectations with 7 cents per...
